Your browser doesn't support javascript.
Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan.
Takeshita, Masaru; Nishina, Naoshi; Moriyama, Saya; Takahashi, Yoshimasa; Uwamino, Yoshifumi; Nagata, Mika; Aoki, Wataru; Masaki, Katsunori; Ishii, Makoto; Saya, Hideyuki; Kondo, Yasushi; Kaneko, Yuko; Suzuki, Katsuya; Fukunaga, Koichi; Takeuchi, Tsutomu.
  • Takeshita M; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 160-8582, Japan. Electronic address: takeshita@a5.keio.jp.
  • Nishina N; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 160-8582, Japan.
  • Moriyama S; Department of Immunology, National Institute of Infectious Diseases, Tokyo, 160-8582, Japan.
  • Takahashi Y; Department of Immunology, National Institute of Infectious Diseases, Tokyo, 160-8582, Japan.
  • Uwamino Y; Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, 160-8582, Japan.
  • Nagata M; Clinical Laboratory, Keio University Hospital, Tokyo, 160-8582, Japan.
  • Aoki W; Clinical Laboratory, Keio University Hospital, Tokyo, 160-8582, Japan.
  • Masaki K; Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 160-8582, Japan.
  • Ishii M; Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 160-8582, Japan.
  • Saya H; Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, 160-8582, Japan.
  • Kondo Y; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 160-8582, Japan.
  • Kaneko Y; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 160-8582, Japan.
  • Suzuki K; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 160-8582, Japan.
  • Fukunaga K; Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 160-8582, Japan.
  • Takeuchi T; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 160-8582, Japan.
Virology ; 555: 35-43, 2021 03.
Article in English | MEDLINE | ID: covidwho-1009919
ABSTRACT
The pandemic of COVID-19 is still ongoing, and many studies on serum antibodies have been reported, however, there are few studies about asymptomatic and mild patients. In this study, we enrolled 44 COVID-19 patients with relatively mild disease and 48 pre-pandemic controls. We measured serum antibodies against extracellular domain, S1 domain, and receptor-binding domain of Spike and N protein, examined neutralization titers by authentic virus neutralization assay and newly-developed bead/cell-based Spike-ACE2 inhibition assay, and compared them with clinical features. Most of these antibodies, including neutralizing titers, were mutually correlated, and the production of antibodies were associated with low Ct values of PCR test, disease severity, symptoms especially pneumonia, lymphopenia, and serological test including CRP, LD, D-dimer, and procalcitonin. Notably, 87.5% of asymptomatic and 23.5% of mild patients did not have antibody against SARS-CoV-2. Our results revealed the inadequate acquisition of humoral immunity in patients with asymptomatic and mild COVID-19 patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / Coronavirus Nucleocapsid Proteins / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Diagnostic study / Prognostic study Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Virology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / Coronavirus Nucleocapsid Proteins / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Diagnostic study / Prognostic study Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Virology Year: 2021 Document Type: Article